Latest news with #NektarTherapeutics
Yahoo
a day ago
- Business
- Yahoo
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
3 days ago
- Business
- Globe and Mail
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Should you invest $1,000 in Nektar Therapeutics right now? Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
San Francisco Chronicle
4 days ago
- Business
- San Francisco Chronicle
OpenAI close to leasing more space in S.F. neighborhood that's becoming popular with tech companies
OpenAI is reportedly close to taking space in a fourth building in San Francisco's Mission Bay that would add to its growing campus in the neighborhood that stretches along the city's waterfront. The maker of ChatGPT, widely regarded as a pioneer in the artificial intelligence space, is said to be in talks to lease space at a building that has long been home to biotech companies, including Nektar Therapeutics, a pharmaceutical company that has had its headquarters based in the property. The talks potentially involve OpenAI's nonprofit arm, according to sources familiar with the deal. The building that is the focus of the negotiations, located at 455 Mission Bay Blvd., spans about 210,000-square-feet and is part of Alexandria's Center for Life Science and Technology, a cluster of life sciences buildings that were constructed by Pasadena-based developer Alexandria Real Estate Equities, or ARE. Neither OpenAI nor ARE, which today owns a minority stake in the larger campus, responded to inquiries from the Chronicle seeking to confirm the pending lease, which an individual with insight into the deal described as being 'close' to completed. CBRE Investment Management, which several years ago acquired a stake in the Alexandria Center campus, also did not respond to messages seeking comment. In recent years, OpenAI has leased massive chunks of space in Mission Bay. The leases come at a time when overall new leasing activity remains subdued in San Francisco, which saw many companies shift to remote work as a result of the COVID-19 pandemic. Last fall, OpenAI leased a 300,000-square-foot building at 550 Terry Francois Blvd., which constituted the city's largest office lease of 2024. The building previously served as the headquarters for Old Navy — Gap Inc., which is Old Navy's parent company, exited the property in 2021. And in October 2023, OpenAI forged a blockbuster lease deal a block from Old Navy's former building, by subleasing two office buildings for a total of 486,600-square-feet from Uber, at 1455 Third St. and 1515 Third St. The 455 Mission Bay property is adjacent to OpenAI's Third Street buildings, and two blocks north of the Chase Center. Inside, about 150,000 square feet are currently available, a majority of which is sublease space, according to real estate insiders. Nektar Therapeutics, which has occupied the building since 2009 and is credited with helping to usher in Mission Bay's biotech boom, has been seeking to sublease its space, according to real estate insiders. In 2023, the company reduced its workforce in the city to just 55 employees. It is unclear whether OpenAI plans to take over the entire building as leases expire. Reports earlier this year indicated that the company was in the market to lease at least 200,000-square feet of additional office space in Mission Bay, which would grow its footprint in the neighborhood to just over 1 million square feet. OpenAI's plan for 455 Mission Bay could be to 'gut it and rebuild it out as office,' particularly if the space is reserved for its nonprofit division, one source told the Chronicle. The source also confirmed that the current lab vacancy in Mission Bay is nearing 50%. Public Records show that ARE last month made moves to expand the amount of office space allocated to its Mission Bay campus, which is currently limited to just over 24,000 square feet. In an application filed with the city's Planning Department, the developer requested that over 500,000 square feet of office space be allocated to the campus, indicating that it plans to pivot from lab to office space there. San Francisco's Proposition M, a law passed decades ago, limits how much office space can be built in the city every year. A total of 950,000 square feet of office space becomes available for allocation in October of each year, of which a majority is reserved for 'large cap' projects of 50,000 square feet or more. But due to a lack of new office developments that have advanced in the city in recent years, the city has seen significantly fewer developers line up for Prop. M office allocation — as of last quarter, nearly one-third of the city's total existing office space sat empty. According to ARE's recent application, nearly 2.5 million square feet of 'Large Cap office space' were available for allocation in the city as of October 2024. If approved, ARE's proposed 500,000 square-foot office allocation in Mission Bay would reduce the amount of office space available for new construction projects to about 2 million square feet, the developer said in its submission to the Planning Department. But with OpenAI and other AI startups increasingly setting their sights on the neighborhood, more office space is needed, the developer stated. The application underscores the neighborhood's gradual evolution from a life sciences hub anchored by UCSF and leading biotech firms, to a hotbed for AI startups and other tech companies. Mission Rock, a new mixed-use campus developed by the San Francisco Giants and Tishman Speyer that has risen within the Mission Bay neighborhood in recent years, has been a target of tech companies looking to expand or relocate. The development recently finalized leases with fintech company Coinbase and Nvidia, America's leading chip maker. 'The AI real estate footprint in the city now exceeds 5 million square feet, including a rapidly expanding presence in Mission Bay, and is leading the recovery of San Francisco's commercial real estate market,' ARE said in its application. The growth in AI is bringing significant investment, talent, and jobs to San Francisco,'
Yahoo
03-08-2025
- Business
- Yahoo
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53%
Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions A total of 17 investors have a majority stake in the company with 50% ownership Insiders have been selling lately We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Nektar Therapeutics (NASDAQ:NKTR) should be aware of the most powerful shareholder groups. With 53% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's delve deeper into each type of owner of Nektar Therapeutics, beginning with the chart below. Check out our latest analysis for Nektar Therapeutics What Does The Institutional Ownership Tell Us About Nektar Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Nektar Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nektar Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 13% of Nektar Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Charles Schwab Investment Management, Inc. is the largest shareholder with 8.3% of shares outstanding. BVF Partners L.P. is the second largest shareholder owning 7.4% of common stock, and Millennium Management LLC holds about 5.4% of the company stock. A closer look at our ownership figures suggests that the top 17 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Nektar Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Nektar Therapeutics in their own names. It has a market capitalization of just US$397m, and the board has only US$4.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. General Public Ownership With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Nektar Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Nektar Therapeutics has 4 warning signs (and 3 which can't be ignored) we think you should know about. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
30-07-2025
- Health
- Medscape
FDA Puts Alopecia Treatment on Fast Track
The FDA has granted a 'Fast Track' designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe alopecia areata, according to a press release from the manufacturer, Nektar Therapeutics. The indication applies to adults and children aged 12 years or older weighing at least 40 kg. REZPEG is a novel biologic that targets 'the interleukin-2 receptor complex in the body to stimulate proliferation of inhibitory immune cells known as regulatory T cells,' according to the company. The Fast Track designation was created to help bring important new treatments to patients as soon as possible and is granted to investigational therapies that may address unmet medical needs for serious conditions, according to the press release. REZPEG is being evaluated in the ongoing Rezolve AA phase 2b study in patients with alopecia areata. In the study, 90 patients with severe-to-very severe alopecia areata (defined as scalp involvement of 50% or more) who were not previously treated with a JAK inhibitor or another biologic were randomized to two different doses of REZPEG or placebo. It will be a self-administered injection, the company said. The primary efficacy endpoint is the mean percent change in the Severity of Alopecia Tool (SALT) score at the end of the 36-week induction period, according to the company. Secondary endpoints include the proportion of participants with reductions in SALT scores of 50% or more at 36 weeks and other timepoints, as well as the mean percent improvement in SALT score at multiple timepoints and the proportion of patients achieving an absolute SALT score ≤ 20. Data from the trial are scheduled to be reported in December 2025, according to the company. The designation follows a previous Fast Track designation for the product as a treatment for moderate-to-severe atopic dermatitis in February.
